J. Bauer

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

M. Buyse, E. Dreher, Torri, 1998, The Lancet.

Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.

R. Stupp, T. Ruhstaller, A. Allal, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial

C. Rochlitz, H. Schmid, M. Borner, 2004, British Journal of Cancer.

Original article Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma

M. Fey, M. Borner, G. Zulian, 2005 .

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

C. Hürny, B. Thürlimann, M. Fey, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer

A. Bardia, A. Guerrero-Zotano, M. Sanders, 2017 .

Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study.

B. Thürlimann, H. Schmid, M. Borner, 2002, European journal of cancer.

Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial.

M. Bolla, P. Maingon, J. Ferrero, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Abstract PD01-07: Transcriptome Analysis of Triple Negative Breast Cancers Identifies Six Distinct Biological Subgroups and Reveals Therapeutic Strategies

M. Sanders, Y. Shyr, B. Lehmann, 2010 .